Patent 11633478 was granted and assigned to Azurity Pharmaceuticals on April, 2023 by the United States Patent and Trademark Office.
Disclosed herein are liquid diluents, formulations, and kits for preparing reconstituted suspensions of a proton pump inhibitor (e.g., omeprazole). The present disclosure also provides formulations for liquid diluents that do not have a tendency for gel formation following exposure to freeze-thaw cycles.